Breaking News
March 19, 2019 - Use of synthetic psychedelic linked to improvements in depression and anxiety
March 19, 2019 - Knee Pain Not Tied to Activity Levels in Knee Osteoarthritis
March 19, 2019 - Study shows benefits of delayed cord clamping in healthy babies
March 19, 2019 - A cell’s “self-destruct” function could yield new therapies
March 19, 2019 - Latest advances and perspectives of all AI types used in pharmaceutical R&D
March 19, 2019 - Prophylactic cranial irradiation used as standard approach for patients with NSCLC
March 19, 2019 - Sugar-sweetened beverages may be linked with increased risk of cardiovascular mortality
March 19, 2019 - AHA News: Black Woman in Their 50s Face Especially High Stroke Risk
March 19, 2019 - Secrets of early life revealed from less than half a teaspoon of blood
March 19, 2019 - Immune cells engineered to tattle on suspicious cells in the body
March 19, 2019 - Heart attack patients who are taken to heart care centres directly survive longer
March 19, 2019 - IVF babies have increased in birthweight over the past 25 years, study reveals
March 19, 2019 - Study highlights the need for psychiatric care to be integrated into cancer treatment
March 19, 2019 - Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients
March 19, 2019 - Caterpillars could hold the secret to new treatment for Osteoarthritis
March 19, 2019 - Parkinson’s treatment delivers a power-up to brain cell ‘batteries’
March 19, 2019 - Stanford launches new Institute for Human-Centered Artificial Intelligence
March 19, 2019 - Wireless earphones may cause cancer
March 18, 2019 - ACC/AHA guideline for prevention of cardiovascular disease released
March 18, 2019 - UTA nursing professor receives $6.575 million to attack musculoskeletal diseases
March 18, 2019 - Gene medication shows promise to treat spinal cord injuries
March 18, 2019 - First Human Study of “Robotic” RaniPill™ Capsule to Replace Injections Announced by Rani Therapeutics
March 18, 2019 - Food Allergy Testing: MedlinePlus Lab Test Information
March 18, 2019 - Altered brain activity patterns of Parkinson’s captured in mice
March 18, 2019 - Apple Heart Study demonstrates ability of wearable technology to detect atrial fibrillation | News Center
March 18, 2019 - Cardiovascular benefits of diabetes drug extend across a wide spectrum of patients, shows study
March 18, 2019 - Novel cardiac pump shows superior outcomes in patients with advanced heart failure
March 18, 2019 - U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
March 18, 2019 - Living like a caveman won’t make you thin—but it might make you healthy
March 18, 2019 - Modified immune cells issue alert when detecting cancer in mice | News Center
March 18, 2019 - Dementia caregivers design robots for alleviating stress and increasing joyful moments
March 18, 2019 - VR technology could help improve balance in humans
March 18, 2019 - Study demonstrates effective way to slow progression of cerebrovascular disease in older adults
March 18, 2019 - Premature babies also have protective anti-viral antibodies
March 18, 2019 - Painkillers taken by pregnant mothers unlikely to cause asthma in the child
March 18, 2019 - Fibromyalgia can be reliably detected in blood samples
March 18, 2019 - Marijuana use has dropped among most teens after legalization
March 18, 2019 - Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)
March 18, 2019 - Researchers identify early home and family factors that contribute to obesity
March 18, 2019 - Fate and festivity: Match Day 2019
March 18, 2019 - Study finds TAVR to be as good as open-heart surgery for patients at low surgical risk
March 18, 2019 - EU-funded project is developing new tools for diagnosing cancer
March 18, 2019 - Gluten, lactose, food dyes in pills could be causing side effects finds study
March 18, 2019 - Taking painkillers during pregnancy is not responsible for asthma risk in children, study shows
March 18, 2019 - Prediagnosis Psychiatric Care Linked to Worse Cancer Mortality
March 18, 2019 - Paris hospital halts stool study after donor deluge
March 18, 2019 - Partial oral antibiotic therapy shows efficacy and safety in patients with infectious endocarditis
March 18, 2019 - Olympus improves access to science education through BioBus collaboration
March 18, 2019 - Depression screening does not improve quality of life in heart attack patients
March 18, 2019 - Echocardiography may aid in patient selection for TMVR
March 18, 2019 - Are ‘Inactive’ Ingredients in Your Drugs Really So Harmless?
March 18, 2019 - Wearable technology can safely identify atrial fibrillation
March 18, 2019 - Scientists tackle rare retinal disease in unique research project
March 18, 2019 - Death By A Thousand Clicks
March 18, 2019 - Absorbable, antibiotic-eluting envelope can reduce rate of cardiac device infections
March 18, 2019 - Hormonal treatment associated with depression in men with prostate cancer
March 18, 2019 - Porvair Sciences launches reinforced 96-well deep round microplate
March 18, 2019 - Simplified catheter ablation could slash waiting lists for atrial fibrillation patients
March 18, 2019 - BFR therapy as part of rehabilitation following ACL surgery may slow bone loss
March 18, 2019 - A human model to test implants for cataract surgery
March 18, 2019 - New risk adjustment model could reduce financial penalty for safety net hospitals
March 18, 2019 - NHS cancer patients’ wait to start treatment worrying
March 18, 2019 - Inventiva Announces Results from Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
March 18, 2019 - Cologuard
March 18, 2019 - Researchers find evidence of prenatal environment tuning genomic imprinting
March 18, 2019 - Dolomite Bio launches novel Nadia product family for single-cell research
March 18, 2019 - Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
March 18, 2019 - Excessive gestational weight gain tied to maternal morbidity
March 18, 2019 - RCEM issues position statement on metrics to supplement four-hour standard target
March 17, 2019 - Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
March 17, 2019 - Brain region plays key role in regulation of parenting behavior, study finds
March 17, 2019 - Natural speed limit on DNA replication sets pace for life’s first steps
March 17, 2019 - New research reveals overlooked impact of herbicide glyphosate on the environment
March 17, 2019 - Molecular patterns could help predict relapse risk in breast cancer patients
March 17, 2019 - Study confirms sensitivity of microbiological cultures for detecting cholera
March 17, 2019 - Scientists Spot Clues to Predicting Breast Cancer’s Return
March 17, 2019 - Scientists identify gene that keeps PTSD-like behavior at bay in female mice
March 17, 2019 - New method would allow doctors to detect earliest stages of cancers in the lymph nodes
March 17, 2019 - Cholesterol protein discovery raises hope for smarter drugs
March 17, 2019 - New insect medium delivers high viable cell density growth and protein yield
Journalist examines OxyContin’s role in opioid crisis

Journalist examines OxyContin’s role in opioid crisis

image_pdfDownload PDFimage_print

Most reporters don’t go into work thinking they’re going to find a story that will occupy them for 17 years.

But that’s what happened to Barry Meier.

In 2001, a person serving on the board regulating Ohio’s pharmacies called an editor at The New York Times to sound the alarm about a drug that appeared to be highly addictive despite company claims that it was resistant to abuse. The editor passed the tip to Meier, who began reporting his first story about OxyContin, a prescription narcotic manufactured by Purdue Pharma.

“I had no idea what a narcotic is. I had no idea what a painkiller is,” Meier said. He picked up the phone and started making calls.

Those phone calls planted the seeds for newspaper reports — and then a book — on the tangled business, medical and law enforcement dynamics of what would balloon into a national crisis of addiction, overdose and crime related to opioids. Published in 2003, the book, Pain Killer, was updated and expanded earlier this year.

Meier recently discussed the complex journey with Paul Costello, Stanford School of Medicine’s chief communications officer, at a recent Health Policy Forum.

“I had no idea this would become the catastrophe — or the scope of the catastrophe — that it’s become,” Meier told the audience. He added:

It’s very disheartening in many ways to see, not just what I wrote about… but all the other warning signs that were driven through, all the other yellow lights that were missed, all the red lights and stop signs that were ignored, by not just drug companies, but by doctors, by public health officials, by lawmakers, by the justice department.

Doctors and drug companies had good intentions when they began looking for better treatment options for patients with chronic pain from non-terminal conditions, such as arthritis and headaches, Meier said. Arriving on the market in 1996, OxyContin appeared to fill that need. Purdue claimed patients taking a moderate dose for long periods of time would not experience withdrawal when they stopped using the narcotic painkiller without tapering off, and that the time-released formula was less subject to abuse.

That was not the case. What’s more, Meier’s reporting for the Times and his book indicates that Purdue executives were aware of OxyContin’s potential for abuse in early years, but did not inform others.

The company admitted misleading marketing tactics for OxyContin in 2007, when Purdue’s parent company pleaded guilty to a federal criminal charge of misbranding the drug and agreed to pay $600 million in penalties. Additionally, three men who had served as top executives for the company each pleaded guilty to individual misdemeanor charges.

Meier told the audience that he later learned that prosecutors had originally wanted to charge the officials with felonies, but top Justice Department officials decided not to move forward with the recommendation. The prosecutors laid out the evidence for the weightier charges in a 120-page memo that Meier acquired about 18 months ago, he said. He wrote about it in a Times article published this year.

The decision not to pursue felony charges against the executives was a pivotal moment for the opioid crisis, Meier told the audience at Stanford:

Had this prosecution gone forward, had this trial gone forward — even if these executives had been found innocent during this trial — the evidence that these prosecutors would have brought to public awareness, to the awareness of doctors, public health officials, legislators, whomever, during the course of this trial would have been an awakening.

Now, Purdue Pharma faces numerous lawsuits from state and local governments, accusing the company of fueling the opioid epidemic through deceptive marketing of OxyContin. The Sackler family, billionaires who own the company, has been named in some of the suits.

While Meier acknowledged the importance of monetary compensation to defray the cost of medical treatment for people who are addicted, he said he hopes the lawsuits are not settled:

The thing that is most important right now, the thing that is going to have the most lasting effect on how medicine is practiced in the future and how public policy is practiced in the future is to have the entire truth of what these companies knew, how they behaved and the steps that they failed to take be made public.

There should be a final public accounting for the hundreds of thousands of lives that have been lost over the last 15 years.

Photo by PhotoLizM

Tagged with:

About author

Related Articles